CoChat
Sign Up
Cited by 269Gout, Hyperuricemia, Uric AcidDrug-Induced Adverse ReactionsBiochemical and Molecular Research

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout

Open access
BECKER, MICHAEL A., SCHUMACHER, H. RALPH, MacDONALD, PATRICIA A., LLOYD, ERIC, LADEMACHER, CHRISTOPHER·2009·The Journal of Rheumatology
DOI 10.3899/jrheum.080814
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective.: To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout. Methods.: Subjects (n = 1086) in this open-label extension study were assigned to fixed-dose daily urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 mg). ULT reassignment was permitted during months 1 to 6 to achieve serum urate (SUA) concentrations between 3.0 and < 6.0 mg/dl. Flares requiring treatment, tophus size, safety, and SUA levels were monitored during up to 40 months of ULT maintenance. Results.: After 1 month initial treatment, > 80% of subjects receiving either febuxostat dose, but only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl compared with subjects receiving febuxostat. Maintenance of SUA < 6.0 mg/dl resulted in progressive reduction to nearly 0 in proportion of subjects requiring gout flare treatment. Baseline tophus resolution was achieved by 46%, 36%, and 29% of subjects maintained on febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respectively. Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups. Conclusion.: Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Registered as NCT00175019.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3899/jrheum.080814

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

Sorted by citations

Items 201–269 of 269

Related

See all

Metadata

Authors
BECKER, M. A., SCHUMACHER, H. R., MacDONALD, P. A., LLOYD, E., & LADEMACHER, C.
Affiliations
  • University of Chicago (US)
  • University of Pennsylvania (US)
  • Takeda (Japan) (JP)
ORCID
BECKER, MICHAEL A.
Venue
The Journal of Rheumatology
Publisher
The Journal of Rheumatology
Published
2009-03-13
Volume
36
Issue
6
Pages
1273-1282
ISSN
  • 0315-162X (ISSN-L)
  • 1499-2752
DOI
10.3899/jrheum.080814
OpenAlex
W2145066076
Cited by
269
References
23
Citations by year
2026: 2 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 21 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 15 · 2014: 24 · 2013: 20 · 2012: 15
FWCI
12.63
Type
journal article
Language
en
Open access
Locations
  • The Journal of Rheumatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
gout, febuxostat, allopurinol, urate-lowering therapy, serum uric acid, gout flares, long-term maintenance therapy, cardiovascular adverse events, drug safety
MeSH terms
Febuxostat, Allopurinol, Gout, Gout Suppressants, Thiazoles, Uric Acid, Treatment Outcome, Hyperuricemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review